Acuta Capital Partners, LLC Madrigal Pharmaceuticals, Inc. Transaction History

Acuta Capital Partners, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$108.54 - $125.2 $3.53 Million - $4.07 Million	-32,500 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$110.06 - $133.7 $3.58 Million - $4.35 Million	32,500 New	32,500 $3.61 Million
Q4 2018 Feb 14, 2019	SELL	$94.77 - $215.54 $3.13 Million - $7.11 Million	-33,000 Closed	0 $0
Q3 2018 Nov 07, 2018	SELL	$207.3 - $300.31 $373,761 - $541,458	-1,803 Reduced 5.18%	33,000 $7.07 Million
Q2 2018 Aug 15, 2018	BUY	$101.55 - $313.9 $3.53 Million - $10.9 Million	34,803 New	34,803 $9.73 Million

295

21.9M

819K

644K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.61B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Acuta Capital Partners, LLC with notifications on news.